Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally

Pursues a research-driven business model focused on the discovery and clinical development of extended half-life monoclonal antibodies, aiming to address unmet needs in immunology and inflammation.What is the remaining capacity for future sales, and how has Dambkowski’s holding shifted over the past year? Direct holdings have declined from 331,948 shares at the start of 2025 to 271,108 after this transaction, reflecting an 18.33% reduction over the period and leaving Dambkowski with approximately 72% of his ...